Gilead Sciences
$1.6B 13F equity value
6 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Gilead Sciences covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RCUS | Arcus Biosciences Inc. | 31,424,760 | $969M | 58.8% |
| LKFT | Lakefront Biotherapeutics | 16,707,477 | $500M | 30.3% |
| ASMB | Assembly Biosciences Inc. | 4,977,089 | $137M | 8.3% |
| KYTX | Kyverna Therapeutics Inc. | 4,126,119 | $37M | 2.2% |
| XLO | Xilio Therapeutics Inc. | 650,389 | $6M | 0.4% |
| ACLX | Arcellx Inc |
Track Gilead Sciences's 13F portfolio: $1.6B in reported holdings, 6 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}